Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.55 |
| ▸ | ACP1 | P24666 | 5/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468833 | 1.00 | AKR1B1 (0.56) | AKR1B1PTPN1ACP1ENPP2PPARG | |
| SCHEMBL5461751 | 0.84 | ENPP2 (0.77) | PTPN1ACP1ENPP2PTPN2PKM | |
| SCHEMBL5461748 | 0.84 | ENPP2 (0.77) | PTPN1ACP1ENPP2PTPN2PKM | |
| SCHEMBL5459960 | 0.83 | MAPK1 (0.69) | AKR1B1PPARGPKMMAPK1NPSR1 | |
| SCHEMBL5459959 | 0.83 | MAPK1 (0.69) | AKR1B1PPARGPKMMAPK1NPSR1 | |
| SCHEMBL5465473 | 0.80 | ENPP2 (0.58) | PTPN1ACP1ENPP2PPARGPTPN2 | |
| SCHEMBL5465471 | 0.80 | ENPP2 (0.58) | PTPN1ACP1ENPP2PPARGPTPN2 | |
| SCHEMBL5460169 | 0.80 | PTPN1 (0.53) | PTPN1ACP1ENPP2PPARGMAPK1 | |
| SCHEMBL5460170 | 0.80 | PTPN1 (0.53) | PTPN1ACP1ENPP2PPARGMAPK1 | |
| SCHEMBL6687446 | 0.79 | PPARG (0.67) | PTPN1ACP1ENPP2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1666469-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | AKR1B1 1236/4885PTPN1 3264/4885ACP1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.